Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 22, 2022 07:30 ET | Source: AC Immune SA

AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update

Seven clinical data readouts expected in 2022Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in...
March 21, 2022 07:30 ET | Source: AC Immune SA

AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative Diseases

LAUSANNE, Switzerland, March 21, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
March 16, 2022 07:41 ET | Source: AC Immune SA

AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference

ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers A-syn PET tracers may be developed to diagnose a-synuclein pathologies, including...
February 28, 2022 07:30 ET | Source: AC Immune SA

AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs

Five presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM) AC Immune’s Chief Medical Officer to participate in expert forum on translational drug discovery...
February 15, 2022 07:30 ET | Source: AC Immune SA

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort

Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment ACI-35.030 continues to be well tolerated with no clinically relevant safety concerns observed...
February 04, 2022 07:30 ET | Source: AC Immune SA

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

Results differentiate ACI-24 as potential best-in-class Abeta vaccine in development Strong response against neurotoxic pyroGlu-Abeta variants observed in non-human primates Data further support...
February 02, 2022 08:58 ET | Source: AC Immune SA

AC Immune to Present at the SVB Leerink 11th Annual Global Healthcare Conference

LAUSANNE, Switzerland, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
December 15, 2021 07:49 ET | Source: AC Immune SA

AC Immune Awarded Two Michael J. Fox Foundation Grants to Advance Small Molecule Parkinson’s Disease Programs

Funding to accelerate the development of first-in-class brain penetrant small molecules to inhibit a-syn aggregation and NLRP3 inflammasome activation in Parkinson’s disease (PD) Programs targeting...
November 12, 2021 08:21 ET | Source: AC Immune SA

AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer’s Vaccine Generates a Potent Immune Response

Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment New data presented at 14th CTAD conference support ACI-35.030’s advancement into late-stage...
November 10, 2021 11:20 ET | Source: AC Immune SA

AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer’s Disease

Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two co-primary endpoints (ADAS-Cog11) with statistically significant reduction in the...